Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

doi:10.1002/cncr.70406

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer - 15 Apr 2026

Coste Arthur, Sritharan Nanthara, Lok Anne, Tomowiak Cécile, Ferrant Emmanuelle, Clavert Aline, Roos-Weil Damien, Bouclet Florian, Caillet Adrien, Croizier Carolyne, Stocker Nicolas, Tchernonog Emmanuelle, Feugier Pierre, Santagostino Alberto, Hivert Bénédicte, Michallet Anne-Sophie, De Guibert Sophie, Lara Diane, Waultier-Rascalou Agathe, Merabet Fatiha, Durand Amandine, Bussot Lucile, Laribi Kamel, Dilhuydy Marie-Sarah, Lévy Vincent, Quinquenel Anne

Abstract excerpt

BACKGROUND: Real-world data are an essential complement to clinical trials. This is particularly true for chronic lymphocytic leukemia, where five first-line options have never been directly compared. METHODS: The authors present the results of a national multicenter real-world study focusing on treatment choices in frontline chronic lymphocytic leukemia (CLL) and the criteria underlying this choice. Patients'...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Benzamides

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazines

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 41983763
DOI: 10.1002/cncr.70406
PMCID: PMC13082195

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.PMID 41983763Read ↗

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Semantic proximity Read ↗

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.Semantic proximity Read ↗

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read ↗

Chronic lymphocytic leukemia in Oman: real-world outcomes, molecular testing gaps, and access to targeted therapy in a low- incidence settingSemantic proximity Read ↗

Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE).Semantic proximity Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Novel agents versus chemotherapy as frontline treatment of CLL.Semantic proximity Read ↗

Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.Semantic proximity Read ↗

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Semantic proximity Read ↗

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.Semantic proximity Read ↗

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?Semantic proximity Read ↗

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.